NKTR

Nektar Therapeutics Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↑ 6/10
  • Value↓ 0/10
Nektar Therapeutics sales and earnings growth
NKTR Growth
Good
  • Revenue Y/Y↓ -72.42%
  • EPS Y/Y↑ 12.91%
  • FCF Y/Y↓ -81.42%
Nektar Therapeutics gross and profit margin trends
NKTR Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -284.20%
  • ROIC 5Y↓ -40.13%
Nektar Therapeutics net debt vs free cash flow
NKTR Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -4.4

Nektar Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks